XRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
XORTX Therapeutics Inc.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 20, 2026
$1.01−0.23 (-18.55%)
Close on Oct 19, 2026
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
0.6%
0M of 7M shares
Institutional holders
6
5 new, 1 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Lincoln Alternative Strategies LLC | 572,470 | 9.90% | 13G (passive) | Oct 23, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of XRTX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Citadel Advisors LLC | 23,116 | 0.33% | $52.47K | New | 0.00% |
| StoneX Group Inc. | 16,369 | 0.24% | $37.90K | New | 0.00% |
| Royal Bank of Canada | 732 | 0.01% | $2.00K | New | 0.00% |
| National Bank Of Canada /Fi/ | 162 | 0.00% | $329 | New | 0.00% |
| Clearstead Advisors, LLC | 55 | 0.00% | $120 | −222 | 0.00% |
| TD Waterhouse Canada Inc. | 9 | 0.00% | $19 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 6 | 0M | 0.6% | 5 / 0 | 1 / 1 | 0M | 0M |
| Q1 2026 | 2 | 0M | 0.2% | 2 / 0 | 0 / 0 | 0M | 0M |